Description: Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.
Home Page: www.crinetics.com
CRNX Technical Analysis
Building No. 2
San Diego,
CA
92121
United States
Phone:
858 450 6464
Officers
| Name | Title |
|---|---|
| Dr. R. Scott Struthers Ph.D. | Founder, Pres, CEO & Director |
| Mr. Jeff E. Knight | Chief Operating Officer |
| Dr. Stephen F. Betz Ph.D. | Founder & Chief Scientific Officer |
| Mr. Marc J. C. Wilson | Chief Financial Officer |
| Ms. Garlan Adams | Gen. Counsel & Corp. Sec. |
| Ms. Adriana Cabre M.B.A. | Chief HR Officer |
| Dr. Alan S. Krasner M.D. | Chief Medical Officer |
| Mr. Kevin Capps | Head of Intellectual Property |
| Mr. James Hassard | Chief Commercial Officer |
| Mr. Chris Robillard M.B.A. | Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4901 |
| Price-to-Sales TTM: | 171.6751 |
| IPO Date: | 2018-07-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 143 |